Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Standard of Care in Latin America for Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Propensity Score Matching Analysis
figure
posted on 2020-10-14, 09:27 authored by Vania Hungria, Deborah M. Martínez-Baños, María-Victoria Mateos, Meletios A. Dimopoulos, Michele Cavo, Bart Heeg, Andrea Garcia, Annette Lam, Gerardo Machnicki, Jianming He, Mariana Fernandez<p>The above summary slide represents the opinions of
the authors. For a full list of declarations, including funding and author
disclosure statements, please see the full text online (see “read the
peer-reviewed publication” opposite).<br></p>
<p>© The authors, CC-BY-NC 2020.<b>
</b></p>
<b><br>
</b>
<p><b> </b></p>
